ADVISORY COMMITTEE CONFLICT-OF-INTEREST WAIVER THRESHOLD OF $100,000
ADVISORY COMMITTEE CONFLICT-OF-INTEREST WAIVER THRESHOLD OF $100,000 is recommended in FDA's "Policy & Guidance: Handbook for FDA Advisory Committees" released June 10. In an appendix on "general principles for excluding SGEs [special government employees] from participating in advisory committee meetings," the agency states that, if an advisory committee member holds a "substantial" interest in a sponsoring company or a competitor, "exclusion appears to be the only course for both members and consultants."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth